DNSP-11 (Dopamine Neuron Stimulating Peptide-11)

GDNF-Derived Peptide | Dopaminergic Neuroprotection

Weight: ~1200 Da
Half-life: Not well characterized
Chain: 11 amino acids
4 studies
2012 latest
1 recent
Limited Research
Dose 100-200mcg per day
Frequency 1x daily (morning recommended)
Cycle 4-6 weeks on, followed by a break
Storage Lyophilized: -20C long-term; Reconstituted: 2-8C, use within 4 weeks

Community Research

Join others researching DNSP-11 — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.

Mechanism of Action

DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.

01 Protects dopaminergic neurons from neurotoxic insults
02 Stimulates dopamine production via tyrosine hydroxylase upregulation
03 Smaller molecule with improved bioavailability compared to full GDNF
04 Does not require GFRalpha1/RET receptor complex for activity
05 Preclinical evidence for neuroprotection in Parkinson's disease models
06 Compatible with intranasal and subcutaneous administration

Molecular Data

Molecular Weight
~1200 Da
Chain Length
11 amino acids
Type
GDNF pro-domain derived peptide
Amino Acid Sequence
One-letter: PPEAPAEDRSL
H₂N
P 1
O ‖ C
N
P 2
O ‖ C
N
E 3
O ‖ C
N
A 4
O ‖ C
N
P 5
O ‖ C
N
A 6
O ‖ C
N
E 7
O ‖ C
N
D 8
O ‖ C
N
R 9
O ‖ C
N
S 10
O ‖ C
N
L 11
COOH
Pro
1

Proline

Position 1

Pro
2

Proline

Position 2

Glu
3

Glutamic Acid

Position 3

Ala
4

Alanine

Position 4

Pro
5

Proline

Position 5

Ala
6

Alanine

Position 6

Glu
7

Glutamic Acid

Position 7

Asp
8

Aspartic Acid

Position 8

Arg
9

Arginine

Position 9

Ser
10

Serine

Position 10

Leu
11

Leucine

Position 11

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Neuroprotection
Dopaminergic Neuron Protection effective

Protects dopamine-producing neurons from neurotoxin-induced damage in preclinical Parkinson's disease models.

Tyrosine Hydroxylase Support effective

Upregulates tyrosine hydroxylase expression, supporting the rate-limiting step in dopamine biosynthesis.

Mitochondrial Function moderate

Supports mitochondrial health in dopaminergic neurons, which is often compromised in neurodegenerative conditions.

Cognitive
Motivation and Drive moderate

Biohacker reports suggest improvements in baseline motivation and drive, consistent with dopaminergic system support.

Mood Baseline moderate

Anecdotal reports of improved mood stability and emotional baseline, likely mediated through dopamine pathway optimization.

Dosing Protocols

Intranasal administration allows for potential direct CNS delivery via olfactory transport, bypassing the blood-brain barrier. This is a popular route in the biohacking community.

GoalDoseFrequencyRoute
General neuroprotection100-200mcg1x dailyIntranasal spray

Reconstitution Instructions

Materials Needed:
  • DNSP-11 lyophilized powder
  • Preservative-free sterile saline
  • Nasal spray bottle
  1. 1 Allow vial to reach room temperature
  2. 2 Reconstitute with preservative-free sterile saline
  3. 3 Calculate concentration per spray based on desired dose
  4. 4 Transfer to nasal spray bottle
  5. 5 Refrigerate reconstituted solution
  6. 6 Alternate nostrils when administering

Interactions

++
Semax
Complementary neurotrophic pathways; Semax acts via BDNF upregulation while DNSP-11 targets dopaminergic neuroprotection through GDNF-related mechanisms.
synergistic
+
Bromantane
Both support dopaminergic function through different mechanisms. Bromantane enhances tyrosine hydroxylase gene expression while DNSP-11 provides neurotrophic support.
compatible
+
9-Me-BC
Both target dopaminergic neuron health. 9-Me-BC promotes dendrite growth and dopamine synthesis; DNSP-11 provides neurotrophic protection.
compatible

What to Expect

Week 1
Subtle changes may begin; most users report minimal noticeable effects during the initial period
Week 2-3
Anecdotal reports of gradual improvement in baseline mood, motivation, and sense of drive
Week 4-6
Potential peak of subjective benefits; improved emotional resilience and cognitive motivation reported by some users
Post-cycle
Limited data on offset timeline; neurotrophic effects may persist beyond active dosing period

Side Effects & Safety

Common Side Effects

  • Nasal irritation or mild burning sensation (intranasal route)
  • Injection site reactions such as redness or swelling (subcutaneous route)

Stop Signs - Discontinue if:

  • Severe or persistent nasal irritation or bleeding
  • Signs of allergic reaction (rash, swelling, difficulty breathing)
  • Unusual neurological symptoms (tremor, involuntary movements)
  • Significant mood disturbances or agitation

Contraindications

  • Pregnancy or breastfeeding
  • Known peptide allergies
  • Very limited human safety data; use at own risk
  • Consult a physician before combining with dopaminergic medications

Quality Checklist

Good Signs

  • White to off-white lyophilized powder
  • Clear, colorless solution after reconstitution
  • Third-party purity testing (target >=95%)
  • Proper cold chain shipping
  • Sealed and sterile packaging

Warning Signs

  • Very limited commercial availability
  • Nasal irritation potential
  • Injection site reactions possible

Bad Signs

  • Cloudy or discolored solution after reconstitution
  • Visible particles or precipitate
  • Powder that fails to dissolve completely

References

  • DNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
    Bradley LH, Fuqua J, Richardson A, et al.
    Neuroscience Letters (2010)

    DNSP-11 protected dopaminergic neurons in a 6-OHDA rat model of Parkinson's disease, preserving tyrosine hydroxylase-positive neurons and improving motor behavior without the side effects associated with full-length GDNF.

  • Dopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's Disease
    Kelps KA, Turchan-Cholewo J, Bhatt I, et al.
    Neuropharmacology (2011)

    A single injection of DNSP-11 provided sustained neuroprotection of dopaminergic neurons over multiple weeks in a 6-OHDA Parkinson's model, demonstrating long-lasting neurotrophic effects from the GDNF pro-domain peptide.

  • DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's Disease
    Fuqua JL, Littrell OM, Lundblad M, et al.
    Society for Neuroscience Abstract (2012)

    DNSP-11 improved motor behavior and restored striatal dopamine neurochemistry in a unilateral 6-OHDA lesion model, supporting its potential as a targeted dopaminergic neuroprotective agent.

  • Identification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1
    Bradley LH, Fuqua JL, Bhatt I, et al.
    Analytical Biochemistry (2012)

    Identified DNSP-11 and a related peptide from the GDNF pro-domain with binding affinity to GFRalpha1, establishing a potential receptor-level mechanism for dopaminergic neuroprotective effects.

Related Peptides

Semax synergistic

Complementary neurotrophic pathways; Semax acts via BDNF upregulation while DNSP-11 targets dopaminergic neuroprotection through GDNF-related mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.